Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2019
August 13, 2019 at 09:16 am
Share
Sunmax Biotechnology Co., Ltd. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced total revenue was TWD 155.074 million compared to TWD 74.675 million a year ago. Operating income was TWD 51.260 million compared to TWD 12.740 million a year ago. Net income was TWD 33.181 million compared to TWD 15.725 million a year ago. Basic earnings per share was TWD 0.61 compared to TWD 0.29 a year ago. For the half year, total revenue was TWD 250.571 million compared to TWD 127.681 million a year ago. Operating income was TWD 69.462 million compared to TWD 18.571 million a year ago. Net income was TWD 55.853 million compared to TWD 31.040 million a year ago. Basic earnings per share was TWD 1.03 compared to TWD 0.57 a year ago.
SunMax Biotechnology Co., Ltd. is a Taiwan-based company principally engaged in research, development, production and distribution of collagen implants and related products. The Company's major products include collagen, collagen implants, microfiber collagen hemostat, collagen absorbable hemostat pads, healthcare products, as well as medical collagen application equipment. Its products are applied in medical and beauty care industrials. The Company distributes its products principally in Taiwan, Mainland China and other regions.